Table 1 Baseline characteristics of trial participants by treatment arma
Characteristic | MVa (n = 200) | Placebo (n = 200) | |
|---|---|---|---|
Sex | Males | 57 (28.5 %) | 66 (33.0 %) |
Females | 143 (71.5 %) | 134 (67.0 %) | |
Age (years) | 18–20 | 9 (4.5 %) | 1 (0.5 %) |
21–30 | 42 (21.0 %) | 58 (29.0 %) | |
31–40 | 85 (42.5 %) | 100 (50.0 %) | |
>40 | 64 (32.0 %) | 41 (20.5 %) | |
Mean ± SDb | 36.9 ± 9.6 | 34.7 ± 8.1 | |
Level of education | None | 7 (3.0 %) | 6 (3.0 %) |
Primary | 103 (51.5 %) | 103 (51.5 %) | |
Secondary | 70 (35.0 %) | 71 (35.5 %) | |
> Secondary | 20 (10.0 %) | 20 (10.0 %) | |
Marital status | Never Married | 19 (9.5 %) | 22 (11.0 %) |
Married/cohabiting | 86 (43.0 %) | 83 (41.5 %) | |
Separated/divorced | 64 (32.0 %) | 59 (29.5 %) | |
Widowed | 31 (15.5 %) | 36 (18.0 %) | |
HB (g/dL) | ≤11.0 | 45 (22.5 %) | 46 (23.0 %) |
>11.0 | 155 (77.5 %) | 154 (77.0 %) | |
Median (IQR)b | 12.2 (11.2–13.2) | 12.3 (11.3–13.5) | |
BMI (kg/m-sq) | <18.5 | 15 (7.5 %) | 16 (8.0 %) |
18.5–24.9 | 122 (61.0 %) | 136 (68.0 %) | |
25.0–29.9 | 43 (21.5 %) | 29 (14.5 %) | |
≥30 | 17 (8.5 %) | 19 (9.5 %) | |
Missing | 3 (1.5 %) | 0 (0.0 %) | |
Time on ART (months) | 0 | 93 (46.5 %) | 108 (54.0 %) |
1–2 | 60 (30.0 %) | 57 (28.5 %) | |
3–6 | 47 (23.5 %) | 35 (17.5 %) | |
Median (IQR)b | 1 (0–2) | 0 (0–1) | |
CD4 count (cells/mm3) | ≤50 | 24 (12.0 %) | 39 (19.5 %) |
51–100 | 42 (21.0 %) | 40 (20.0 %) | |
101–200 | 77 (38.5 %) | 73 (36.5 %) | |
>200 | 53 (26.5 %) | 46 (23.0 %) | |
Missing | 4 (2.0 %) | 2 (1.0 %) | |
Median (IQR)b | 144.5 (86.0–215.3) | 137.0 (68.0–192.0) | |
MV use duration (months) | 0 | 159 (79.5 %) | 153 (76.5 %) |
1–2 | 36 (18.0 %) | 42 (21.0 %) | |
>2 | 5 (2.5 %) | 5 (2.5 %) | |